{"entity":{"id":"arp-senegal","kind":"institution","name":"Agence sénégalaise de Réglementation pharmaceutique (ARP)","aka":["ARP","ARP Sénégal","Senegalese Pharmaceutical Regulatory Agency"],"tldr":"Senegal's medicines regulator, created by decree in April 2022. It registers medicines, licenses pharmaceutical establishments, oversees clinical trials and runs pharmacovigilance. WHO lists it at maturity level 3 for medicines and vaccines, announced in 2024.","summary":"Decree 2022-824 of 7 April 2022 created the Agence sénégalaise de Réglementation pharmaceutique and set its rules of organisation. Its stated mission is to carry out the regulatory functions of national pharmaceutical policy, control the pharmaceutical sector and enforce the laws on pharmacy, medicines and other health products, pharmaceutical establishments, medical biology laboratories, testing and calibration laboratories and clinical trials. Its director general is Dr Aïssatou Sougou. The coordinates are an approximate Dakar city point.\n\nThe agency sets out its work against WHO's Global Benchmarking Tool: marketing authorisation, vigilance, market surveillance and control, licensing of establishments, inspection, laboratory testing, clinical trial oversight, lot release for vaccines, and approval and oversight of blood products. WHO's list of regulators at maturity levels 3 and 4, dated August 2026, gives ARP maturity level 3 for medicines and vaccines (non-producing), announced in 2024. Its own site, read on 11 November 2026, carries the banner that Senegal is the first country of French-speaking Africa to reach maturity level 3; that ranking is ARP's claim, not WHO's. Adverse effects can be reported to it through the Med Safety app or its online form.","asOf":"2026-11-11","links":[{"label":"ARP: about the agency, decree 2022-824 and missions","url":"https://www.arp.sn/a-propos"},{"label":"ARP: regulatory functions","url":"https://www.arp.sn/fonctions-reglementaires"},{"label":"WHO: regulatory authorities at maturity levels 3 and 4 (PDF, August 2026)","url":"https://www.who.int/publications/m/item/list-of-nras-operating-at-ml3-and-ml4"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["senegal-ministry-of-health","who"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dakar","country":"SN","lat":14.7,"lng":-17.46,"institutionType":"government","website":"https://www.arp.sn","programs":["Marketing authorisation of medicines","Pharmacovigilance (Med Safety)","Clinical trial oversight","Licensing and inspection of pharmaceutical establishments","Laboratory quality control"]},"route":"/institutions/arp-senegal/","neighbours":{"institution":[{"id":"senegal-ministry-of-health","kind":"institution","name":"Ministère de la Santé et de l'Hygiène publique, Senegal","route":"/institutions/senegal-ministry-of-health/"},{"id":"who","kind":"institution","name":"World Health Organization Cancer Programme","route":"/institutions/who/"}]}}